SNSteven Nicolaides

Steven Nicolaides

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven Nicolaides has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy

    by Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan

    Background/Aims: The residual risk of colectomy after infliximab salvage in steroid-refractory acute severe ulcerative colitis (ASUC) is required to inform the need for subsequent maintenance biologic therapy. The aim of this study was to determine the dynamic response of common serum biomarkers to infliximab salvage and assess their utility in predicting subsequent colectomy.Methods: A retrospective single-center cohort study was conducted on all patients who received infliximab salvage for steroid-refractory ASUC between January 1, 2010, and July 31, 2019. Biomarkers were assessed on admission and days 1 and 3 post infliximab, and included C-reactive protein (CRP)-albumin-ratio (CAR), CRP-lymphocyte-ratio (CLR), platelet-lymphocyte-ratio (PLR) and neutrophil-lymphocyte-ratio (NLR).Results: Of 94 patients (median age, 35 years; 67% of male), 20% required colectomy at 12 months. Biomarkers on day 3 post-infliximab best differentiated nonresponders, who had higher CRP, lower albumin and lower lymphocyte count (each P< 0.05). Day 3 predictive performance (area under the curve) for 12-month colectomy was best for CAR (0.871) and CLR (0.874), which were similar to Lindgren (0.829; P> 0.05) but superior to Mayo (0.726), partial Mayo (0.719), PLR (0.719), Ho index (0.714), NLR (0.675), Travis score (0.657) and endoscopic Mayo (0.609) (each P< 0.05). A day 3 CAR cutoff of 0.47 mg/g had 79% sensitivity, 80% specificity, 94% negative predictive value (NPV) to predict colectomy; while a day 3 CLR cutoff of 6.0 mg/109 had 84% sensitivity, 84% specificity, 96% NPV.Conclusions: CAR and CLR measured on day 3 post infliximab salvage for steroid-refractory ASUC represent simple and routinely performed biomarkers that appear to be strong predictors of colectomy. Prospective studies are required to confirm the utility of these predictive scores.


  • Open Access

    The impact of tobacco smoking on treatment choice and efficacy in inflammatory bowel disease

    by Steven Nicolaides, Abhinav Vasudevan, Tony Long, Daniel van Langenberg

    Smoking significantly increases the risk of developing and worsens Crohn’s disease (CD), yet protects against the development and reduces the severity of ulcerative colitis. It is less clear whether smoking impacts the efficacy of therapeutics in inflammatory bowel disease (IBD). We review the literature regarding the relationship between smoking and the efficacy of medical and surgical therapy in IBD. Smoking is associated with alterations in thiopurine metabolism and may affect time to disease relapse. The outcomes of anti-tumor necrosis factor therapy in active smokers appear neutral with data lacking for newer biologics. Smoking increases the risk of postoperative recurrence in those requiring resection for CD, likely attributable to perturbations of the gut microbiota although further implications of these for disease onset/progression and treatment efficacy remain unclear. Multiple lifestyle and psychosocial confounders are likely under-recognized cofactors in the association between smoking and IBD. Despite the widely promulgated risks associated with cigarette smoking in CD, more incisive data are required to further elucidate the actual relationship between smoking and disease pathways, while accounting for the several negative cofactors prevalent in smokers which cast uncertainty on the magnitude of the direct effect of smoking on disease pathophysiology and the efficacy of therapy.


  • Editorial: methotrexate vs azathioprine-do differential rates of discontinuation settle the debate? Authors' reply

    by Abhinav Vasudevan, Danny Con, Steven Nicolaides, Daniel R. van Langenberg

  • Letter: rationalising aminosalicylates in inflammatory bowel disease

    by Steven Nicolaides, Abhinav Vasudevan, Daniel van Langenberg


  • Open Access

    Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease

    by Abhinav Vasudevan, Nina Parthasarathy, Danny Con, Steven Nicolaides, Ross Apostolov, Ayushi Chauhan, Maria Bishara, Raphael P. Luber, Neetima Joshi, Anna Wan, et al.

    Background There are safety concerns regarding immunomodulators (thiopurines and methotrexate) for treatment of inflammatory bowel disease (IBD). Aim To compare the long‐term tolerability, and persistence of thiopurine and methotrexate therapy in IBD. Methods A retrospective cohort study was performed at two hospitals between 1 January 2004 and 31 December 2016 for patients commenced on thiopurines or methotrexate for IBD. Treatment discontinuation rates, intolerances and disease activity were obtained from medical records. Results There were 782 patients commenced on immunomodulator therapy; 244 (31%) on methotrexate with folate (67% subcutaneous therapy) and 538 (69%) on thiopurine (73% azathioprine). Median follow‐up was 42 vs 47 months (P = 0.09). In patients on thiopurines, median 6‐TGN was 298 pmol/8 x 108 RBCs, while the median dose of methotrexate was 25 mg weekly. Methotrexate recipients had a higher rate of prior immunomodulator intolerance, were typically older and had a longer disease duration (54% vs 3%, median 43 vs 36 years, 6 vs 5 years, respectively, each P < 0.05). Overall, 208 (27%) discontinued therapy due to adverse events, (40% on methotrexate vs 19% on thiopurines, P < 0.001), including nausea (18% vs 4%), fatigue (7% vs 2%) and hepatotoxicity (8% vs 2%, each P < 0.001). Hospitalisations from adverse events (0.8% vs 0.9%) and serious infections (9% vs 12%), and deaths (1% vs 0%) were comparable between groups (all P > 0.05). Discontinuation due to adverse events occurred later in patients on methotrexate than on thiopurines (median 7 vs 5 months, P = 0.08). Conclusion Discontinuation of methotrexate occurred at rates twice that of dose‐optimised thiopurine therapy.


  • Aminosalicylate withdrawal following escalation to immunomodulators or biologics in ulcerative colitis: cost saving, convenient and does not compromise efficacy

    by Steven Nicolaides, Abhinav Vasudevan, Daniel Ross Langenberg

    Background Aminosalicylates are widely used in ulcerative colitis (UC) and often continued despite treatment escalation, perhaps given a lack of evidence or consensus guiding dose reduction or cessation. The aim was to compare long‐term outcomes in patients who escalated treatment and either continued or discontinued aminosalicylate therapy. Methods Consecutive patients diagnosed with UC ≥1y prior escalation to immunomodulator or biologic therapy while concurrently taking aminosalicylates, were compared based on dis‐ versus continuation of aminosalicylates once clinical remission was achieved (denoted as baseline). The primary endpoint was time (from baseline) to treatment failure, defined as requiring steroids, resumption of aminosalicylates or surgery. Successful discontinuation was achieved if no treatment failure occurred throughout follow‐up. The resultant cost savings per patient‐year gleaned by aminosalicylate discontinuation were calculated. Results Of 128 patients meeting inclusion criteria, 71 discontinued and 57 continued aminosalicylates post‐escalation. Median disease duration was 8.2 and 8.7y (p=0.2), time from escalation to baseline 1.8 and 2.9y (p=0.1) respectively. Post‐escalation, median time on immunomodulator was longer, yet no difference in time on biologics was observed, with successful aminosalicylate discontinuation (versus unsuccessful) (2.9 vs 1.2y (p=0.03), 0.4 vs 0.6y (p=0.8) respectively). Kaplan‐Meier survival analysis demonstrated no difference in proportion of treatment failure in the groups post‐baseline (Breslow test, p=0.4), yet aminosalicylate discontinuation yielded cost savings of $AUD 2000 per patient‐year. Conclusions These real‐world data support discontinuation of aminosalicylates after achieving remission with either immunomodulator or biologic therapy in UC, at minimal risk of relapse yet enabling significant reductions in cost and tablet burden.


  • Complex Fistulizing Crohn’s Disease

    by Ross Apostolov, Steven Nicolaides, Abhinav Vasudevan

  • Open Access

    Inflammatory bowel disease and superior mesenteric artery thromboembolism

    by Steven Nicolaides, Abhinav Vasudevan, Daniel Van Langenberg

    While patients with inflammatory bowel disease are known to be at increased risk of venous thromboembolism, the risk of arterial thrombosis is less well recognized. Here, we describe the case of a middle-aged female with a recent diagnosis of Crohn's disease who presented to her local emergency department with acute abdominal pain. Subsequent investigations revealed a thrombus in the superior mesenteric artery resulting in multi-organ infarction requiring major infra-abdominal surgery and extensive resection of segments of small and large bowel.